Emergent Biosolutions Inc. (EBS) Stock Price & Analysis
Emergent Biosolutions Inc. (EBS) fell 3.20% to USD 7.26 as of July 26, 2026 at 12:25 UTC, according to Nexqual real-time market data.
EBS last closed at USD 7.5; the session ranged USD 7.24–7.65 on volume of 456,035 shares. Market capitalization is —, with a 52-week range of USD 5.62–14.06 (NYQ). Source: Nexqual, July 26, 2026 at 12:25 UTC.
Key Statistics (as of July 26, 2026 at 12:25 UTC)
| Price | USD 7.26 |
|---|---|
| Change | ▼ 3.20% (down) |
| Previous Close | USD 7.5 |
| Open | USD 7.51 |
| Day Range | USD 7.24 – 7.65 |
| 52-Week Range | USD 5.62 – 14.06 |
| Volume | 456,035 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (EBS)
Nexqual's technical model rates EBS "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 12:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.59 (neutral) |
| vs SMA50 | Below (USD 8.15) |
| MACD | -0.21 (negative) |
Analyst Ratings (EBS)
Wall Street analysts rate EBS "None", per Nexqual as of July 26, 2026 at 12:25 UTC.
| Consensus Rating | None |
|---|
Earnings (EBS)
| Next Earnings Date | 2026-08-05 |
|---|
Source: Nexqual, July 26, 2026 at 12:25 UTC.
Financials & Fundamentals (EBS)
| Total Revenue | $676.80M |
|---|---|
| Revenue Growth (YoY) | -29.70% |
| Gross Margin | +47.49% |
| Operating Margin | +6.79% |
| Profit Margin | -1.27% |
| ROE | -1.60% |
| Debt / Equity | 111.76 |
| Current Ratio | 4.29 |
| Total Cash | $160.30M |
| Total Debt | $584.60M |
| Free Cash Flow | $256.21M |
Source: Nexqual, July 26, 2026 at 12:25 UTC.
Financial Health Score (EBS)
Nexqual rates Emergent Biosolutions Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 12:25 UTC.
| Growth | Critical — Revenue -30% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 7% |
| Balance Sheet | Mixed — $160M cash vs $585M debt |
| Cash Flow | Strong — FCF $256M, 38% margin |
| Efficiency | Critical — ROE -2%, ROA 3.4% |
Ownership (EBS)
| Insider Ownership | +3.85% |
|---|---|
| Institutional Ownership | +87.09% |
| Float | 49.38M |
| Short % of Float | +20.35% |
Source: Nexqual, July 26, 2026 at 12:25 UTC.
Leadership (EBS)
Emergent Biosolutions Inc. is led by Joseph C. Papa Jr., M.B.A., R.Ph. (age 69), CEO, President & Director, per Nexqual as of July 26, 2026 at 12:25 UTC.
| CEO, President & Director | Joseph C. Papa Jr., M.B.A., R.Ph. (age 69) |
|---|---|
| Executive VP & CFO | Richard S. Lindahl (age 61) |
| Executive Vice President of Quality, Ethics & Compliance | Coleen Glessner (age 54) |
| Senior Vice President of Products Business | Paul A. Williams (age 58) |
| Senior Vice President of Manufacturing & Bioservices | William Hartzel (age 47) |
Major Backers & Investors (EBS)
Notable institutional backers of Emergent Biosolutions Inc. include American Century Companies Inc, Charles Schwab Investment Management, Inc., Acadian Asset Management. LLC, according to Nexqual as of July 26, 2026 at 12:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 9.37% |
| Charles Schwab Investment Management, Inc. | 2.92% |
| Acadian Asset Management. LLC | 2.68% |
| Palisade Capital Management, L.P. | 2.33% |
| Charles Schwab | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.76% |
| Vanguard Group | 11.72% |
| State Street | 8.81% |
| Dimensional Fund Advisors | 5.34% |
| Geode Capital | 2.47% |
Source: Nexqual, July 26, 2026 at 12:25 UTC.
From Emergent Biosolutions Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
- It operates through Commercial Products, MCM Products, and All Other Revenues segments.
- It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose.
- In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VIR | Vir Biotechnology, Inc. | USD 8.69 | ▼ 7.06% |
| QDEL | QuidelOrtho Corporation | USD 16.05 | ▼ 3.78% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 271.77 | ▲ 1.79% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 59.33 | ▲ 1.59% |
| BHVN | Biohaven Ltd. | USD 14.32 | ▼ 2.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 12:25 UTC. This page is informational and not investment advice.